Entity

Time filter

Source Type

Banjara Hills, India

Patnala S.R.C.M.,Neuland Laboratories Ltd | Patnala S.R.C.M.,Jawaharlal Nehru Technological University | Patnala S.R.C.M.,Village Green | Khagga M.,Jawaharlal Nehru Technological University | Bhavani R.,Village Green
Asian Journal of Chemistry | Year: 2015

Nitazoxanide [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate] is a drug used for antiprotozoal treatment. This drug belongs to biopharmaceutics classification system (II) and presently available in two high oral dosage forms-tablet (500 mg) and oral suspension (100 mg per 5 mL when reconstituted). A monotropically more stable novel polymorphic form (Form II) of nitazoxanide with improved aqueous solubility has been identified and fully characterized by a variety of analytical techniques such as powder X-ray diffraction, differential scanning calorimeter, thermogravimetric analysis, Karl Fischer titration, infrared spectroscopy, solution state nuclear magnetic resonance, polarized microscopy and high performance liquid chromatography techniques. Aqueous solubility of Form II is increased by 2.76 folds. Form II is obtained from less toxic and environment friendly Class III organic solvent ethanol.


Patent
NEULAND LABORATORIES Ltd | Date: 2013-04-08

An improved process for preparation of Olanzapine pamoate monohydrate from Olanzpaine is disclosed which comprises mixing at room temperature a solution of olanzapine prepared in water in presence of an acid, with a solution of pamoic acid prepared in water in presence of a base; stirring and maintaining the reaction mixture for a sufficient time till precipitation of solid and drying the solid to obtain olazapine pamoate monohydrate.


Patent
NEULAND LABORATORIES Ltd | Date: 2013-04-08

The present invention provides a process for the preparation of sugammadex sodium involving the step of: reacting 6-perdeoxy-6-per-halo-gamma-cyclodextrin with 3-mercapto propionic acid in the presence of alkali metal alkoxide in an organic solvents. The invention also provides a process for purifying the sugammadex or its pharmaceutically acceptable salts using water and organic solvents.


Lahoti A.M.,Neuland Laboratories Ltd | Ravi P.,Neuland Laboratories Ltd | Kumar N.P.,Neuland Laboratories Ltd | Innareddy V.,Neuland Laboratories Ltd | And 4 more authors.
Pharmaceutical Technology | Year: 2015

Febuxostat is a novel, non-purine, selective inhibitor of xanthine oxidase for hyperuricemia in patients with gout. It is the first promising substitute for allopurinol in 40 years. Various synthetic routes to febuxostat, as well as polymorphic forms and impurities of the drug, are reported in the literature. The authors have also identified several impurities that result from the synthesis of febuxostat. This article describes the identification and control of all isomeric, carryover, and byproduct impurities of febuxostat and its intermediates. © Patheon Inc. All rights reserved.

Discover hidden collaborations